Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Gynecol Oncol. 2017 Jul 27;146(3):477–483. doi: 10.1016/j.ygyno.2017.07.135

Figure 3. Overall survival.

Figure 3

1 Hazard ratios are reported for rates on Paclitaxel+Reovirus to Paclitaxel Alone. This analysis occurred after the primary analysis was conducted.

2 Analysis stratified by measurable disease (Yes/No) and platinum-free interval (≤ 182 days versus > 182 days).